BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLRX BioLine Rx

Post-Mkt 07-16 19:56:46 EDT

2.98

+0.07

+2.41%

盘后2.98

+0.000.00%

16:10 EDT

High3.07	Low2.90	Vol7.37K
Open3.07	D1 Closing2.91	Amplitude5.84%
Mkt Cap12.97M	Tradable Cap12.44M	Total Shares4.35M
T/O22.05K	T/O Rate0.18%	Tradable Shares4.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLRX","market":"US","secType":"STK","nameCN":"BioLine Rx","latestPrice":2.98,"timestamp":1784232000000,"preClose":2.91,"halted":0,"volume":7370,"hourTrading":{"tag":"盘后","latestPrice":2.98,"preClose":2.98,"latestTime":"16:10 EDT","volume":42,"amount":125.16,"timestamp":1784232603963,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.024054982817869358,"floatShares":4173500,"shares":4351357,"eps":-1.8408,"marketStatus":"Post-Mkt","change":0.07,"latestTime":"07-16 19:56:46 EDT","open":3.07,"high":3.07,"low":2.9001,"amount":22047,"amplitude":0.058385,"askPrice":3.33,"askSize":100,"bidPrice":2.54,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.8408,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1784246400000},"marketStatusCode":4,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":2.91,"postHourTrading":{"tag":"盘后","latestPrice":2.98,"preClose":2.98,"latestTime":"16:10 EDT","volume":42,"amount":125.16,"timestamp":1784232603963,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.764808,"impliedVol":1.9134,"impliedVolPercentile":0.3426},"requestUrl":"/m/hq/s/BLRX","defaultTab":"news","newsList":[{"id":"2649998244","title":"BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649998244?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:25","pubTimestamp":1783509921,"startTime":"0","endTime":"0","summary":"BioLineRx (BLRX) announced new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft model...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-hemispherian-announces-new-preclinical-data-on-glix1-parp-inhibitor-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-hemispherian-announces-new-preclinical-data-on-glix1-parp-inhibitor-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943372","title":"JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943372?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:41","pubTimestamp":1780404070,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Bioline RX Ltd Sponsored ADR today and set a price target of $12.00. According to TipR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-bioline-rx-ltd-sponsored-adr-blrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294332","title":"Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640294332?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:41","pubTimestamp":1780404062,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BLRX","ONC","HCSG","XLV","BK4581","BK4585","LABU","BK4588","BK4082","BK4526","BK4139","AMIX","LU0128526141.USD","LU0029874061.USD","XBI","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638500504","title":"BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2638500504","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638500504?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:02","pubTimestamp":1779879777,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent.  This is a 87.06 percent increase over sales of $255.000 thousand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52801859/bioline-rx-q1-sales-477-000k-beat-343-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638048955","title":"Press Release: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2638048955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638048955?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:00","pubTimestamp":1779879600,"startTime":"0","endTime":"0","summary":"- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma  -. - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide -resistant patient-derived xenograft model -. - Management to host conference call today, May 27, at 8:30 am EDT -. TEL AVIV, Israel, May 27, 2026 /PRNewswire/ -- BioLineRx Ltd.  , a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721428933.USD","PDX","BLRX","CDX","IE00BYQQ9H92.USD","LU2211817866.USD","BK4195","BK4211","IE00B5TLWC47.USD","IE00BFXG0V08.USD","PFS","R","BK4588","BK4585","LU0347712357.USD","BK4232","LU2413666699.HKD","BK4121","BK4139","BK4567","LU2413666426.HKD","BK4022","BK4548","LU1093756168.USD","BK4533","LU1093756325.SGD","MTD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638558357","title":"BioLine RX Ltd  expected to post a loss of $1.04 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2638558357","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638558357?lang=en_us&edition=fundamental","pubTime":"2026-05-25 20:32","pubTimestamp":1779712322,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of $1.04 a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a rise in quarterly revenue when it reports  results on May 27 for the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nL8N4220HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636516853","title":"BioLineRx and Hemispherian report new GLIX1 anti-tumor effect in GBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2636516853","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636516853?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:13","pubTimestamp":1779189198,"startTime":"0","endTime":"0","summary":"BioLineRx (BLRX) and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced highly encouraging ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biolinerx-and-hemispherian-report-new-glix1-anti-tumor-effect-in-gbm-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biolinerx-and-hemispherian-report-new-glix1-anti-tumor-effect-in-gbm-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BLRX","AS","BK4202"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621306705","title":"BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621306705","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621306705?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:06","pubTimestamp":1774357604,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.54) by 37.04 percent.  The company reported quarterly sales of $194.000 thousand which missed the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51430236/bioline-rx-q4-epads-0-34-beats-0-54-estimate-sales-194-000k-miss-651-598k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770568","title":"BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770568","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770568?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:16","pubTimestamp":1774264582,"startTime":"0","endTime":"0","summary":"BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent.  This is a 98.35 percent decrease over sales of $11.749 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51401341/bioline-rx-q4-sales-194-000k-miss-651-598k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621772207","title":"Press Release: BioLineRx Reports 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2621772207","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621772207?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma  by end of this month -. - GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -. - Management to host conference call today, March 23, at 8:30 am EDT -. TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2463526074.USD","BK4548","BK4211","IE00BFXG0V08.USD","LU2413666426.HKD","ASH","LU1721428933.USD","LU1093756325.SGD","IE00BYQQ9H92.USD","PFS","LU2413666699.HKD","BK4533","IE00B5TLWC47.USD","SCD","BK4121","LU0347712357.USD","BK4109","MTD","BLRX","BK4585","BK4567","LU1093756168.USD","BK4139","LU2211817866.USD","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739374","title":"BioLine RX Ltd  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739374","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739374?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:02","pubTimestamp":1774011739,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of77cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a fall in quarterly revenue when it reports  results on March 23 for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N408197:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620478831","title":"Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2620478831","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620478831?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:45","pubTimestamp":1773989100,"startTime":"0","endTime":"0","summary":"BioLineRx Ltd. (NASDAQ: BLRX) to release Q4 earnings on March 23. Previous Q3 losses were 22 cents per share, with sales of $427,000. Analysts rate the stock favorably.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/20/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/20/Analyst-Woman-Working-With-Information-D.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372528/top-wall-street-forecasters-revamp-biolinerx-expectations-ahead-of-q4-earnings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372528/top-wall-street-forecasters-revamp-biolinerx-expectations-ahead-of-q4-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BLRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620422172","title":"BioLine RX Ltd  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620422172","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620422172?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:43","pubTimestamp":1773751400,"startTime":"0","endTime":"0","summary":"BioLine RX Ltd  expected to post a loss of77cents a share - Earnings Preview BioLine RX Ltd BLRX.OQ, BLRX.O is expected to  show a fall in quarterly revenue when it reports  results  for the period en","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL8N40514T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BLRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biolinerx.com","stockEarnings":[{"period":"1week","weight":-0.0332},{"period":"1month","weight":-0.1032},{"period":"3month","weight":0.2176},{"period":"6month","weight":0.0104},{"period":"1year","weight":-0.3562},{"period":"ytd","weight":0.0505}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0},{"period":"3month","weight":0.0757},{"period":"6month","weight":0.0913},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.072241},{"month":2,"riseRate":0.4,"avgChangeRate":-0.047168},{"month":3,"riseRate":0.2,"avgChangeRate":-0.102622},{"month":4,"riseRate":0.4,"avgChangeRate":-0.016375},{"month":5,"riseRate":0.6,"avgChangeRate":0.112777},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.040987},{"month":7,"riseRate":0.466667,"avgChangeRate":0.019441},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.055209},{"month":9,"riseRate":0.4,"avgChangeRate":-0.015821},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.018467},{"month":11,"riseRate":0.266667,"avgChangeRate":-0.053503},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.069939}],"exchange":"NASDAQ","name":"BioLine Rx","nameEN":"BioLine Rx","securityTypeName":"DR","adrRate":"1:600"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioLine Rx,BLRX,BioLine Rx股票,BioLine Rx股票老虎,BioLine Rx股票老虎国际,BioLine Rx行情,BioLine Rx股票行情,BioLine Rx股价,BioLine Rx股市,BioLine Rx股票价格,BioLine Rx股票交易,BioLine Rx股票购买,BioLine Rx股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioLine Rx(BLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioLine Rx(BLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}